1篇
您的检索式：作者名="Zhenyi Niu"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials显示文摘Lung cancer is the leading cause of cancer-related death across the world.Unlike lung adenocarcinoma,patients with lung squamous cell carcinoma(LSCC)have not benefitted from targeted therapies.Although immunotherapy has significantly improved cancer patients’outcomes,the relatively low response rate and severe adverse events hinder the clinical application of this promising treatment in LSCC.Therefore,it is of vital importance to have a better understanding of the mechanisms underlying the pathogenesis of LSCC as well as the inner connection among different signaling pathways,which will surely provide opportunities for more effective therapeutic interventions for LSCC.In this review,new insights were given about classical signaling pathways which have been proved in other cancer types but not in LSCC,including PI3K signaling pathway,VEGF/VEGFR signaling,and CDK4/6 pathway.Other signaling pathways which may have therapeutic potentials in LSCC were also discussed,including the FGFR1 pathway,EGFR pathway,and KEAP1/NRF2 pathway.Next,chromosome 3q,which harbors two key squamous differentiation markers SOX2 and TP63 is discussed as well as its related potential therapeutic targets.We also provided some progress of LSCC in epigenetic therapies and immune checkpoints blockade(ICB)therapies.Subsequently,we outlined some combination strategies of ICB therapies and other targeted therapies.Finally,prospects and challenges were given related to the exploration and application of novel therapeutic strategies for LSCC. | Zhenyi Niu Runsen Jin Yan Zhang Hecheng Li | 2022 | Signal Transduction and Targeted Therapy2022，7，11： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员